Charles Schwab
CNTB

Charles Schwab’s Connect Biopharma Holdings CNTB Stock Holding History

Charles Schwab’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.5K Buy
+36,760
New +$89.1K ﹤0.01% 3414

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Charles Schwab's CNTB Position: Q2 2026 in Review

Charles Schwab opened a new position in Connect Biopharma Holdings (CNTB) in Q2 2026: 36,760 shares worth $87.5K. The stake represents ﹤0.01% of the portfolio and ranks #3414 among its holdings.

56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • Charles Schwab held 36,760 shares of Connect Biopharma Holdings worth $87.5K as of Q2 2026.
  • Connect Biopharma Holdings was a new Charles Schwab position in Q2 2026.
  • Connect Biopharma Holdings made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3414 holding.
  • 56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.